- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Lexaria to Conduct First Webinar Market Update on November 1
Lexaria Bioscience (CSE:LXX,OTCQB:LXRP) announced that it will be conducting its first webinar market update on Wednesday November 1.
Lexaria Bioscience (CSE:LXX,OTCQB:LXRP) will be conducting its first webinar market update on Wednesday November 1, at 4:15 PM Eastern / 1:15 PM Pacific.
This meeting is open to everyone but registration is required. REGISTER NOW for this important event:https://events.genndi.com/register/169105139238467429/ce8311a9b6
During this webinar, the company will discuss its latest developments, deliver a short corporate presentation and host questions from the audience.
Click here to connect with Lexaria Bioscience (CSE:LXX,OTCQB:LXRP) for an Investor Presentation
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.